Core Insights - Incyte (INCY) has shown strong performance, reaching a 52-week high of $87.24 on August 18, with a subsequent slight dip to $85.46, resulting in a 26.8% increase in stock price compared to the industry’s 6.3% gain [1][8]. Financial Performance - Jakafi sales increased by 15% to $1.5 billion in the first half of 2025, while Opzelura sales surged 37% year over year to $283 million during the same period [5][7][8]. - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen to $6.07 from $5.77 over the past 30 days, with the 2026 EPS estimate increasing by 36 cents to $7.49 [21]. Product Pipeline and Regulatory Updates - The FDA approved a cream formulation of ruxolitinib (Opzelura) for mild to moderate atopic dermatitis and non-segmental vitiligo, marking it as the first topical JAK inhibitor approved in the U.S. [6][8]. - Incyte's oncology portfolio has been bolstered by FDA approvals for Monjuvi and Zynyz, expanding treatment options for various cancers [9][12]. - The collaboration with Qiagen aims to develop a diagnostic panel for myeloproliferative neoplasms, enhancing Incyte's pipeline [13][14]. Competitive Landscape - Incyte's reliance on Jakafi for revenue growth is significant, as it accounts for over 70% of total revenues, and competition is increasing with new entrants like GSK's Ojjaara [15][16][23]. - The patent protection for Jakafi is expected to expire in the coming years, posing a potential risk to future revenue streams [17]. Management and Strategic Direction - Incyte has appointed Bill Meury as the new CEO, indicating a potential shift in strategic direction [23].

Core Viewpoint - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] Group 1: Market Performance - Since reaching a historical high on September 3, 2024, healthcare stocks have been in a "persistent downtrend," underperforming both in absolute terms and relative to the S&P 500 [1] - August is identified as a turning point for the sector, with healthcare stocks beginning to reverse their previous weak performance [1] Group 2: Economic Environment - The recovery is driven by a historically significant valuation gap and an economic backdrop characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors the healthcare sector [1] - The dual effect of valuation discount and improved sentiment provides strong justification for including healthcare stocks in investment portfolios under the current economic conditions [2] Group 3: Investment Recommendations - Evercore ISI highlights several healthcare stocks with attractive valuations and sentiment, including Cencora (COR.US), BioMarin Pharmaceutical (BMRN.US), Cigna (CI.US), Cardinal Health (CAH.US), Humana (HUM.US), Incyte (INCY.US), LabCorp (LH.US), Pfizer (PFE.US), Quest Diagnostics (DGX.US), Teleflex (TFX.US), Tenet Healthcare (THC.US), Universal Health Services (UHS.US), and Viatris (VTRS.US) [2]

Group 1 - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] - Healthcare stocks have been in a "persistent downtrend" since reaching historical highs on September 3, 2024, missing out on market rebounds [1] - The recovery is driven by a historical valuation gap and a macroeconomic environment characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors healthcare sector performance [1] Group 2 - The current price-to-earnings ratio of the overall market is 25.5 times, while healthcare stocks still present attractive investment options [2] - The potential recovery of healthcare stocks is described as part of "the fastest bear market rebound in history," indicating a larger bull market may extend until 2026 [2] - Evercore ISI recommends healthcare stocks with both valuation and sentiment appeal, including Cencora, BioMarin Pharmaceutical, Cigna, Cardinal Health, Humana, Incyte, Labcorp, Pfizer, Quest Diagnostics, Teleflex, Tenet Healthcare, Universal Health Services, and Viatris [2]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum characteristics, with A being the highest score [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Style Score focuses on identifying undervalued stocks using metrics like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial health and future growth potential through earnings, sales, and cash flow analysis [4] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings estimate changes to identify favorable investment opportunities [5] VGM Score - The VGM Score combines the three Style Scores to highlight stocks with the best value, growth, and momentum characteristics [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.75% since 1988 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to narrow down choices [8] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks, even with good Style Scores, may still face declining earnings forecasts, increasing the risk of price drops [10] Company Spotlight: Incyte Corporation - Incyte Corporation, based in Wilmington, DE, is a biopharmaceutical company focused on proprietary therapeutics [11] - Currently rated 3 (Hold) with a VGM Score of A and a Value Style Score of B, indicating attractive valuation metrics [12] - The company has seen upward revisions in earnings estimates, with a Zacks Consensus Estimate of $5.77 per share for fiscal 2025 and an average earnings surprise of +4.2% [12]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Core Insights - Incyte Corporation reported strong second-quarter 2025 results, with adjusted earnings of $1.57 per share, surpassing the Zacks Consensus Estimate of $1.39, and a significant improvement from an adjusted loss of $1.82 per share in the same quarter last year [2][10] Financial Performance - Total revenues for the second quarter reached $1.22 billion, reflecting a 16% year-over-year growth, driven by the performance of Jakafi and Opzelura, and exceeding the Zacks Consensus Estimate of $1.15 billion [3][10] - Jakafi sales amounted to $763.8 million, an 8% increase from the previous year, beating the Zacks Consensus Estimate of $744.1 million [4][10] - Opzelura cream generated $164.5 million in sales, a 35% year-over-year increase, surpassing the Zacks Consensus Estimate of $148.6 million [5][10] - Newly approved Zynyz generated $8.9 million in sales, significantly up from the previous year and exceeding the Zacks Consensus Estimate of $2.7 million [6] - Iclusig sales were $32.7 million, up 22% year over year, beating the Zacks Consensus Estimate of $29 million [6] - Pemazyre sales reached $22.2 million, reflecting a 9% increase and surpassing the Zacks Consensus Estimate of $20.2 million [6] - Minjuvi's revenues were $31.1 million, flat year over year, missing the Zacks Consensus Estimate of $34.3 million [7] - Axatilimab-csfr (Niktimvo) recorded $36.2 million in sales in its second quarter post-launch [8] Guidance and Future Outlook - The company raised its 2025 guidance for Jakafi revenues to a range of $3-$3.05 billion, up from the previous estimate of $2.95-$3 billion, while maintaining Opzelura's guidance at $630-$670 million [10][18] - Adjusted R&D expenses are now expected to be between $1.82-$1.84 billion, an increase from the prior guidance of $1.78-$1.81 billion [18] - Adjusted SG&A expenses are projected to be in the range of $1.16-$1.19 billion [18] Market Performance - Incyte's shares have increased by 1.6% year to date, outperforming the industry growth of 0.6% [9]

Core Insights - Incyte Corporation reported a second-quarter revenue of $1.22 billion, a 16% increase year over year, surpassing the consensus estimate of $1.15 billion [1] - The adjusted earnings per share were $1.57, a significant improvement from a loss of $1.82 a year ago, and also beating the consensus estimate of $1.41 [1] Financial Performance - Jakafi's net product revenue increased by 8% to $764 million, driven by an 8% rise in paid demand across all indications [9] - Opzelura's net product revenue rose by 35% to $164 million, attributed to increased patient demand and refills for atopic dermatitis and vitiligo [9] - Minjuvi/Monjuvi's net product revenue remained stable at $31.13 million [9] Future Guidance - The company raised its revenue guidance for Jakafi to $3 billion—$3.05 billion for 2025, up from the previous guidance of $2.95 billion—$3 billion [4] - Other oncology net product revenues are now expected to be $500 million—$520 million, an increase from the prior guidance of $415 million—$455 million [4] - Opzelura's sales guidance remains unchanged at $630 million—$670 million, with expectations of double-digit CAGR in the U.S. and internationally over the next several years [5] Product Development and Market Position - Incyte has several important product launches planned between now and 2030, focusing on transitioning to new durable product growth drivers by 2029 [6] - The FDA approved Monjuvi in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma [3] - The FDA extended the review period for Opzelura for children aged 2-11 years with mild to moderate atopic dermatitis, with a new action date set for September 19 [8] Market Sentiment - Despite the positive financial results, analysts express concerns about the long-term outlook due to the loss of exclusivity for Jakafi at the end of 2028 [6] - William Blair rates Incyte stock at Market Perform, indicating that while there are opportunities for growth, near-term clinical readouts may not significantly change investor sentiment [7][10]

Core Insights - Incyte reported $1.22 billion in revenue for Q2 2025, a 16.5% year-over-year increase, with an EPS of $1.57 compared to -$1.82 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] - The company’s revenue and EPS surprises were +5.56% and +12.95% respectively, indicating stronger performance than analysts anticipated [1] Revenue Breakdown - Product royalty revenues reached $151.12 million, surpassing the estimated $145.98 million, reflecting a 10.2% increase year-over-year [4] - Net product revenues for Iclusig were $32.73 million, exceeding the $28.99 million estimate, marking a 21.8% year-over-year growth [4] - Total net product revenues amounted to $1.06 billion, above the $985.29 million estimate, showing a 16.9% increase year-over-year [4] - Net product revenues for Pemazyre were $22.19 million, compared to the $20.24 million estimate, representing a 9.5% year-over-year change [4] - Net product revenues for Minjuvi/Monjuvi were $31.13 million, slightly below the $34.25 million estimate, with a minimal year-over-year change of 0.1% [4] - Net product revenues for Opzelura reached $164.5 million, exceeding the $148.56 million estimate, reflecting a significant 35.2% year-over-year increase [4] - Net product revenues for Jakafi were $763.79 million, surpassing the $744.1 million estimate, with an 8.2% year-over-year growth [4] - Net product revenues for Zynyz were $8.92 million, significantly above the $2.73 million estimate, indicating a remarkable 1270.4% year-over-year increase [4] - Royalty revenues for Olumiant were $33.48 million, slightly below the $33.57 million estimate, with a 5.6% year-over-year increase [4] - Royalty revenues for Tabrecta were $6.63 million, below the $6.88 million estimate, reflecting a 25.2% year-over-year increase [4] - Royalty revenues for Jakavi were $109.71 million, exceeding the $103.35 million estimate, with a 10.5% year-over-year change [4] - Net product revenues for Niktimvo were $36.15 million, significantly above the $20.33 million estimate [4] Stock Performance - Incyte's shares returned +3% over the past month, compared to the Zacks S&P 500 composite's +3.6% change, indicating a performance in line with the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]

Company Performance - Incyte reported quarterly earnings of $1.57 per share, exceeding the Zacks Consensus Estimate of $1.39 per share, and showing a significant improvement from a loss of $1.82 per share a year ago, resulting in an earnings surprise of +12.95% [1] - The company achieved revenues of $1.22 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.56%, and up from $1.04 billion in the same quarter last year [2] - Over the last four quarters, Incyte has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Outlook - Incyte shares have increased approximately 1.6% since the beginning of the year, underperforming compared to the S&P 500's gain of 8.6% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the upcoming quarter is $1.57 on revenues of $1.22 billion, and for the current fiscal year, it is $5.77 on revenues of $4.71 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Incyte belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Incyte's stock performance [5]

Financial Data and Key Metrics Changes - Total product revenues for Q2 reached $1,060 million, a 17% increase year-over-year, driven by strong demand for Jakafi and Opsilura, as well as contributions from Nictimvo's launch [22][20] - Total revenues were $1,220 million, up 16% compared to the same period last year [22] - Jakafi net product revenue was $764 million for Q2, representing an 8% growth year-over-year [22] - Opsilura's total net product revenue for Q2 was $164 million, a 35% increase year-over-year [23] - The company raised its full-year revenue guidance for Jakafi to a range of $3,000 million to $3,050 million [22] Business Line Data and Key Metrics Changes - Opsilura's U.S. net product revenue was $132 million, up 19% year-over-year, driven by increased patient demand [24] - Nictimvo's net product revenues in Q2 were $36 million, with strong commercial execution and high patient need [25] - Other hematology-oncology products generated net product revenues of $131 million, a 66% year-over-year increase, primarily due to the Nectinvo launch [27] Market Data and Key Metrics Changes - Opsilura has close to 20,000 prescribers and is showing strong growth across atopic dermatitis and vitiligo [9] - Nictimvo achieved approximately 82% account penetration with rapid uptake in BMT centers across the U.S. [25] - The company expects continued strong performance in the pediatric indication for Opsilura, with an FDA approval anticipated in September [20] Company Strategy and Development Direction - The company aims to build a comprehensive plan for acceleration that includes R&D productivity, operating expenses, and capital allocation [11] - Strategic priorities include taking care of core products, accelerating product development, and careful capital allocation [16][19] - The focus is on converting scientific advancements into regulatory approvals and business results, particularly in hematology oncology and immunology [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for new product flow and emphasized the importance of execution in driving growth [19][40] - The company is navigating challenges to transition to new product growth drivers by 2029 [8] - Management highlighted the strong demand for Jakafi and Opsilura, with expectations for continued growth if execution remains strong [20][40] Other Important Information - The company recorded a benefit of $242 million from a contract dispute settlement with Novartis, which also reduced COGS [28] - R&D expenses for Q2 were $495 million, with an increase of 8% year-over-year, driven by investments in late-stage development assets [29] - The company plans to present full Phase III results for ruxolitinib cream and advance povastatinib in three indications, with significant opportunities for revenue creation [38][39] Q&A Session Summary Question: Importance of therapeutic areas at Incyte - Management indicated that MPNs are the most important therapeutic area, with a focus on transforming treatment in this space [44][45] Question: Read-through from Kallar data for ET and expectations for MF - Management noted that the mechanism of action for the mutant CalR antibody suggests a high probability of success in MF based on ET data [54][55] Question: Initial data for six seventeen F and enthusiasm for povastatin - Management explained that the delay in data release is due to the need for higher doses and longer follow-up to obtain comprehensive data [60] Question: Dynamics of Nictimvo launch and inventory impact - Management highlighted strong penetration in the market and noted that inventory accounted for less than 5% of Q2 sales, indicating strong demand [77] Question: Balancing investment in pipeline advancement and external opportunities - Management emphasized the importance of capital allocation and the need to evaluate both internal and external investments without forcing a specific ratio [97][100]